FUNDAMENTALS · Fundamentals · TW Financial Services

Diamond Biofund (6901) Fundamentals 2026 — Revenue Analysis | SniperIQ

Diamond Biofund (6901) is a TW-listed Financial Services company in Investment - Banking & Investment Services with a market capitalization of NT

4.9B, trading at NT
7.50 on the TAI. This SniperIQ fundamentals page covers Diamond Biofund's valuation, profitability (net margin 126.7%), revenue (-NT$596,000 in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapNT
4.9B
Net Margin126.7%
Revenue (FY25)-NT$596,000

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Diamond Biofund's market cap?

Diamond Biofund (6901) has a market capitalization of approximately NT

4.9B, trading at NT
7.50 on the TAI. Market cap moves with the live share price.

What is Diamond Biofund's P/E ratio?

Diamond Biofund's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 1.7x. Valuation multiples are best compared with Financial Services sector peers rather than read in isolation.

How profitable is Diamond Biofund?

Diamond Biofund runs a net profit margin of 126.7%, a gross margin of 60.9%, and an operating margin of 78.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Diamond Biofund generate?

Diamond Biofund reported revenue of -NT$596,000 for fiscal year 2025, with net income of -NT

.2B and earnings per share (EPS) of -1.38. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Diamond Biofund pay a dividend?

Diamond Biofund does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Diamond Biofund financially healthy?

Diamond Biofund carries a debt-to-equity ratio of 0.01x and a current ratio of 109.47x, with a market beta of 0.93. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Diamond Biofund a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Diamond Biofund (6901) the key facts are: market cap NT

4.9B, revenue -NT$596,000, 52-week range 12.05-22.4. Weigh valuation, profitability, growth, and balance-sheet strength against Financial Services peers and form your own view.

Track Diamond Biofund's full fundamentals live

Get Diamond Biofund's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Washington H. Soul Pattinson and (SOL) fundamentals · Saudi Tadawul Group Holding (1111) fundamentals · Mercuria Holdings (7347) fundamentals · Everest Group (EG) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons